| Secondary |
| Myocardial Infarction |
41.5% |
| Hypertension |
17.0% |
| Chronic Obstructive Pulmonary Disease |
8.6% |
| Lipid Metabolism Disorder |
8.6% |
| Hyperlipidaemia |
7.5% |
| Thrombosis Prophylaxis |
3.8% |
| Drug Use For Unknown Indication |
2.4% |
| Osteoporosis |
1.3% |
| Dyslipidaemia |
1.1% |
| Hyperphosphataemia |
1.1% |
| Ischaemic Heart Disease Prophylaxis |
1.1% |
| Upper Gastrointestinal Haemorrhage |
1.1% |
| Blood Creatine Phosphokinase Increased |
0.8% |
| Transient Ischaemic Attack |
0.8% |
| Atrial Fibrillation |
0.5% |
| Constipation |
0.5% |
| Dizziness |
0.5% |
| Gastritis |
0.5% |
| Hernia |
0.5% |
| Hypoaesthesia |
0.5% |
|
| Pneumonia |
20.4% |
| Bronchiolitis |
8.2% |
| Pyrexia |
8.2% |
| Galactorrhoea |
6.1% |
| Respiratory Distress |
6.1% |
| Rhabdomyolysis |
6.1% |
| Granulocyte Count Decreased |
4.1% |
| Hepatitis Acute |
4.1% |
| Hyperprolactinaemia |
4.1% |
| Interstitial Lung Disease |
4.1% |
| Liver Disorder |
4.1% |
| Pain In Extremity |
4.1% |
| Upper Respiratory Tract Inflammation |
4.1% |
| Weight Loss Poor |
4.1% |
| Cerebral Haemorrhage |
2.0% |
| Constipation |
2.0% |
| Lymphocyte Stimulation Test Positive |
2.0% |
| Platelet Count Decreased |
2.0% |
| Rectal Haemorrhage |
2.0% |
| Renal Impairment |
2.0% |
|
| Concomitant |
| Hypertension |
14.2% |
| Hyperlipidaemia |
12.3% |
| Hepatitis C |
10.3% |
| Prophylaxis |
8.9% |
| Drug Use For Unknown Indication |
6.1% |
| Chronic Hepatitis C |
6.0% |
| Rheumatoid Arthritis |
5.8% |
| Diabetes Mellitus |
5.7% |
| Cardiac Failure |
4.0% |
| Product Used For Unknown Indication |
3.9% |
| Angina Pectoris |
3.2% |
| Iron Deficiency Anaemia |
2.9% |
| Insomnia |
2.7% |
| Gastritis |
2.4% |
| Osteoporosis |
2.3% |
| Constipation |
2.2% |
| Gastric Ulcer |
1.9% |
| Type 2 Diabetes Mellitus |
1.9% |
| Hyperuricaemia |
1.8% |
| Hypercholesterolaemia |
1.6% |
|
| Anaemia |
16.3% |
| Platelet Count Decreased |
9.3% |
| Rash |
7.7% |
| White Blood Cell Count Decreased |
7.0% |
| Renal Impairment |
5.4% |
| Vomiting |
5.4% |
| Renal Disorder |
4.8% |
| Malaise |
4.5% |
| Hypoglycaemia |
4.2% |
| Pancreatitis Acute |
3.8% |
| Shock |
3.8% |
| Drug Eruption |
3.5% |
| Interstitial Lung Disease |
3.5% |
| Loss Of Consciousness |
3.2% |
| Renal Failure Acute |
3.2% |
| White Blood Cell Count Increased |
3.2% |
| Hepatic Function Abnormal |
2.9% |
| Oedema |
2.9% |
| Sepsis |
2.9% |
| Cardiac Failure |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
85.9% |
| Onychomycosis |
5.1% |
| Arteriosclerosis |
1.3% |
| Atrial Fibrillation |
1.3% |
| Cardiac Failure |
1.3% |
| Cerebral Infarction |
1.3% |
| Cerebrovascular Accident Prophylaxis |
1.3% |
| Constipation |
1.3% |
| Gastrooesophageal Reflux Disease |
1.3% |
|
| Drug Interaction |
40.0% |
| Condition Aggravated |
20.0% |
| Dementia |
20.0% |
| Hepatic Function Abnormal |
20.0% |
|
